Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly.
Eli Lilly & Co. Inc.’s stock rose 2.3% Wednesday, after the company said its Zepbound weight-loss drug was more effective ...
Shares of Eli Lilly climbed early Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss ...
People who took Zepbound lost 17 pounds more on average after 72 weeks of treatment than those who were given Novo Nordisk’s ...
The trial enrolled 751 adults with obesity or overweight conditions and at least one weight-related medical problem ...
President-elect Donald Trump and his incoming administration are unlikely to attempt a wholesale restructuring of U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback